Covid-19 vaccine giant Serum Institute says told to prioritise India

A healthcare worker looks on as a nurse prepares a dose of the AstraZeneca’s COVISHIELD vaccine, during the coronavirus disease vaccination campaign, at a medical centre in Mumbai, India, January 16, 2021. — Reuters pic
A healthcare worker looks on as a nurse prepares a dose of the AstraZeneca’s COVISHIELD vaccine, during the coronavirus disease vaccination campaign, at a medical centre in Mumbai, India, January 16, 2021. — Reuters pic

Subscribe to our Telegram channel for the latest updates on news you need to know.


NEW DELHI, Feb 22 — The world’s biggest vaccine maker, India’s Serum Institute, has urged other countries to be “patient” about it supplying anti-coronavirus shots, saying it has been instructed to prioritise its home market.

“Dear countries & governments, as you await #COVISHIELD supplies, I humbly request you to please be patient,” Serum chief Adar Poonawalla tweeted yesterday.

“@SerumInstIndia has been directed to prioritise the huge needs of India and along with that balance the needs of the rest of the world. We are trying our best.”

Serum, from its sprawling facility in Pune in western India, is producing hundreds of millions of doses of the AstraZeneca vaccine.

Many countries around the world, particularly poorer nations, are relying heavily on the company for supplies of the vaccine, and it has already shipped millions of doses abroad.

The Serum Institute also plans to supply 200 million doses to Covax, a World Health Organization-backed effort to procure and distribute inoculations to poor countries.

Poonawalla did not say who had told the firm to prioritise India, or whether the instructions were new.

India’s aim of inoculating 300 million people by July is falling well behind schedule with just over 11 million shots given so far.

The problems however are thought to lie more with not enough people coming forward for the vaccinations rather than problems with supplies of the shots. — AFP

Related Articles